Unison Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Unison Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $10.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Unison Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $10.6M Trade | TransData Nexus

Unison Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Lipid & Metabolism Specialist · $10.6M Total Trade · DGFT Verified

Unison Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $10.6M across 4 products in 3 therapeutic categories. Based on 397 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ezetimibe ($5.0M), Apixaban ($3.9M), Rivaroxaban ($1.1M).

Unison Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Unison Pharmaceuticals Private Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Unison Pharmaceuticals Private Limited? — Company Overview & Market Position

Unison Pharmaceuticals Private Limited, established on June 1, 2001, in Ahmedabad, Gujarat, India, is a privately held pharmaceutical company specializing in the development, manufacturing, and marketing of finished pharmaceutical formulations. The company operates under the Corporate Identification Number (CIN) U24232GJ2001PTC079092. As of the financial year ending March 31, 2024, Unison reported a total revenue of ₹300.59 crore, reflecting a 29.61% increase from the previous year. The company's authorized capital stands at ₹10 crore, with a paid-up capital of ₹8.81 crore. Unison employs approximately 1,434 professionals, indicating a robust workforce dedicated to its operations. The registered office is located at Unison House, Nr. Prernatirth Derasar Nr. Ratnadeep-II, Satellite, Jodhpur, Ahmedabad, Gujarat, 380015.

What Does Unison Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ezetimibe$5.0M 2Apixaban

Product Portfolio — Top 4 by Export Value

Unison Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ezetimibe	Lipid & Metabolism	$5.0M	227	1.0%	7
2	Apixaban	Cardiovascular	$3.9M	114	2.2%	8
3	Rivaroxaban	Cardiovascular	$1.1M	41	2.1%	12
4	Terbinafine	Antifungals	$632.6K	15	2.3%	9

Unison Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $10.6M. The top category is Lipid & Metabolism (47.1% of portfolio), followed by Cardiovascular (47.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Unison Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Unison Pharmaceuticals operates two state-of-the-art manufacturing facilities that adhere to stringent Good Manufacturing Practice (GMP) standards. These facilities are accredited by the European Union (EU), Therapeutic Goods Administration (TGA), and other regulatory agencies, ensuring compliance with international quality standards. The manufacturing units are equipped to produce a diverse range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic segments. (pharmasource.global)

3Key Leadership

The leadership team at Unison Pharmaceuticals is headed by Managing Director Bhagyesh Nitinbhai Shah, who has been at the helm since October 27, 2013. Nitin Rasiklal Shah serves as a Director, also appointed on October 27, 2013. Under their guidance, the company has experienced significant growth, with a 29.61% increase in total operating revenue for the financial year ending March 31, 2024.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Unison Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Unison Pharmaceuticals has made significant strides in regulated markets, obtaining approvals from various international regulatory bodies. The company's manufacturing facilities hold certifications from the European Union (EU) and the Therapeutic Goods Administration (TGA), indicating compliance with stringent quality standards. These approvals facilitate Unison's entry into markets such as the EU and Australia, where regulatory compliance is paramount. Additionally, the company's products are registered in countries like Kenya and Uganda, expanding its reach in the African market. (pharmasource.global)

2Emerging Markets

Unison Pharmaceuticals has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are registered in Kenya and Uganda, enhancing its footprint in the African continent. While specific details regarding registrations in Latin America and Southeast Asia are not provided, Unison's commitment to global expansion suggests ongoing efforts to penetrate these regions. The company's adherence to international quality standards, as evidenced by its GMP certifications, positions it favorably for market access in these emerging economies. (pharmasource.global)

3Geographic Strategy

Unison Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Unison Pharmaceuticals' interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly available. The company's focus on markets such as the EU, Australia, and Africa suggests that its primary regulatory engagements may be concentrated in these regions. However, without explicit information, a comprehensive assessment of Unison's FDA status cannot be provided.

2WHO & EU GMP

Unison Pharmaceuticals' manufacturing facilities are accredited with Good Manufacturing Practice (GMP) certifications from the European Union (EU) and the World Health Organization (WHO). These certifications attest to the company's commitment to maintaining high-quality standards in its manufacturing processes. The EU GMP certification is particularly significant, as it facilitates access to European markets, where regulatory compliance is stringent. The WHO GMP certification further underscores Unison's adherence to global quality standards, enhancing its credibility in international markets. (pharmasource.global)

CDSCO & Indian Regulatory

Unison Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Unison Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific competitors in overlapping therapeutic categories are not identified, the company's diverse product portfolio and international certifications position it favorably in the market. The absence of publicly available data on market share comparisons and head-to-head analyses limits a comprehensive competitive assessment. Nonetheless, Unison's strategic focus on both domestic and international markets, along with its commitment to quality, suggests a competitive edge in the industry.

2Key Differentiators

Unison Pharmaceuticals' key differentiators include its extensive experience of over four decades in the pharmaceutical industry, a diverse product portfolio spanning various therapeutic segments, and manufacturing facilities accredited with EU and WHO GMP certifications. These strengths enable the company to offer high-quality, cost-effective pharmaceutical products that meet international standards. Additionally, Unison's strategic expansion into both regulated and emerging markets demonstrates its adaptability and commitment to global healthcare solutions.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Unison Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Unison Pharmaceuticals has demonstrated a strong track record in the pharmaceutical industry, with a significant increase in total operating revenue by 29.61% for the financial year ending March 31, 2024. The company maintains a consistent export volume, with a total export value of $10.6 million USD across 397 shipments from 2022 to 2026. The product portfolio is concentrated, with the top five products accounting for 100% of exports, indicating a focused approach to its offerings. The company's adherence to international quality standards, as evidenced by its GMP certifications, and its strategic expansion into both regulated and emerging markets, reflect its reliability and commitment to delivering quality pharmaceutical products.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the product is listed in the FDA's Orange Book, indicating approval for sale in the U.S. market.

WHO-GMP Certification: Verify the WHO-GMP certificate issued by the World Health Organization, which can be obtained from the manufacturer's official website or the WHO's official site.

Frequently Asked Questions — Unison Pharmaceuticals Private Limited

How many pharmaceutical products does Unison Pharmaceuticals Private Limited export from India?

Unison Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Ezetimibe ($5.0M), Apixaban ($3.9M), Rivaroxaban ($1.1M), Terbinafine ($632.6K). Total export value is $10.6M.

What is Unison Pharmaceuticals Private Limited's total pharmaceutical export value?

Unison Pharmaceuticals Private Limited's total pharmaceutical export value is $10.6M, based on 397 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Unison Pharmaceuticals Private Limited cover?

Unison Pharmaceuticals Private Limited exports across 3 therapeutic categories. The largest are Lipid & Metabolism (47.1%, 1 products), Cardiovascular (47.0%, 2 products), Antifungals (6.0%, 1 products).

Get Full Unison Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.